SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)
Clin. transl. oncol. (Print)
; 20(1): 22-28, ene. 2018. tab, ilus
Artículo
en Inglés
| IBECS
| ID: ibc-170464
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life (AU9
RESUMEN
No disponible
Texto completo:
Disponible
Colección:
Bases de datos nacionales
/
España
Base de datos:
IBECS
Asunto principal:
Glioblastoma
Tipo de estudio:
Estudio diagnóstico
/
Guía de práctica clínica
/
Estudio pronóstico
Aspecto:
Preferencia del paciente
Límite:
Humanos
Idioma:
Inglés
Revista:
Clin. transl. oncol. (Print)
Año:
2018
Tipo del documento:
Artículo
Institución/País de afiliación:
Complejo Hospitalario Universitario de Granada Virgen de las Nieves/Spain
/
Complejo Hospitalario de Navarra/Spain
/
Hospital Ramón y Cajal/Spain
/
Hospital Ruber Internacional/Spain
/
Hospital Universitari Germans Trias i Pujol de Badalona/Spain
/
Hospital Universitari Vall dHebron/Spain
/
Hospital Universitario de Salamanca/Spain
/
Institut Català dOncologia (ICO)/Spain
/
Parc de Salut Mar/Spain
